Editors' ChoiceCancer

From MDS/AML to iPSC and back again

+ See all authors and affiliations

Science Translational Medicine  08 Mar 2017:
Vol. 9, Issue 380, eaam9861
DOI: 10.1126/scitranslmed.aam9861

You are currently viewing the abstract.

View Full Text

Abstract

iPSC lines derived from MDS and AML patient samples can map clonal evolution, disease progression and regression, and identify disease stage–specific medication effects.

View Full Text

Related Content